Targovax AS, of Oslo, Norway, reported immune activation data from the first four patients in its phase I trial testing ONCOS-102, which uses oncolytic viruses as a neoantigen therapeutic cancer vaccine, followed by the checkpoint inhibitor (CPI) Keytruda (pembrolizumab, Merck & Co. Inc.) in patients with advanced melanoma whose disease has progressed after prior CPI treatment.